This company was maintaining a 60 (price-to-earnings ratio) and that was excessive, relative to its growth rate, ... Now, it's more reasonably priced. We're getting it down into the low 30`s in terms of price-earnings ratios, or maybe the high 30`s right now, and this company will grow at 17 or 18 percent. So Pfizer looks good, at this point.
|